Title:Application of Targeted Therapy to Malignant Gliomas and Response to Treatment
VOLUME: 8 ISSUE: 1
Author(s):Eudocia Q. Lee, Andrew D. Norden, Jan Drappatz and Patrick Y. Wen
Affiliation:Center for Neuro-Oncology, Dana Farber/ Brigham and Women' s Cancer Center, 450 Brookline Avenue, SW 430, Boston, MA 02215.
Keywords:Targeted therapy, malignant glioma, angiogenesis, clinical trials, multi-targeted therapy, "malignant
gliomas", cellular signaling kinases
Abstract:The prognosis for malignant gliomas remains poor despite multimodality therapy. An increased understanding
of the molecular pathogenesis involved in glioma development and growth has resulted in development of agents that
specifically target these molecular processes and pathways. Except for inhibitors of the vascular endothelial growth factor
pathway, results from most single agent trials have been modest at best. Tailoring therapy to the individual patients is an
attractive strategy although most studies have failed to determine predictive biomarkers. Numerous novel agents, multitargeted
agents, and combination therapies are now in clinical trials for malignant glioma.
